Cargando…

PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer

BACKGROUND: Personalized and effective treatments for pancreatic ductal adenocarcinoma (PDAC) continue to remain elusive. Novel clinical trial designs that enable continual and rapid evaluation of novel therapeutics are needed. Here, we describe a platform clinical trial to address this unmet need....

Descripción completa

Detalles Bibliográficos
Autores principales:	Douglas, Julia E., Liu, Suyu, Ma, Junsheng, Wolff, Robert A., Pant, Shubham, Maitra, Anirban, Tamm, Eric P., Bhosale, Priya, Katz, Matthew H. G., Varadhachary, Gauri R., Koay, Eugene J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722115/ https://www.ncbi.nlm.nih.gov/pubmed/34980020 http://dx.doi.org/10.1186/s12885-021-09095-7

Ejemplares similares

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study
por: Zaid, Mohamed, et al.
Publicado: (2020)

Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer
por: Koay, Eugene J., et al.
Publicado: (2019)

Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy
por: Amer, Ahmed M., et al.
Publicado: (2018)

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma
por: Liu, Qingqing, et al.
Publicado: (2017)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

THE PANC 3 SCORE PREDICTING SEVERITY OF ACUTE PANCREATITIS
por: BEDUSCHI, Murilo Gamba, et al.
Publicado: (2016)

Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
por: Gong, Jun, et al.
Publicado: (2023)

Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience
por: Bhutani, Manoop S., et al.
Publicado: (2019)

3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma
por: Kang, Ya’an, et al.
Publicado: (2022)

The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer
por: Perri, Giampaolo, et al.
Publicado: (2020)

Investigating the Mitochondrial Permeability Transition Pore in Disease Phenotypes and Drug Screening
por: Bhosale, Gauri, et al.
Publicado: (2019)

Assessment of PANC3 Score in Predicting Severity of Acute Pancreatitis
por: Shah, Avreen Singh, et al.
Publicado: (2017)

Quantitative imaging to evaluate malignant potential of IPMNs
por: Hanania, Alexander N., et al.
Publicado: (2016)

Glycolysis in Panc-1 human pancreatic cancer cells is inhibited by everolimus
por: LIU, LING, et al.
Publicado: (2013)

P86 PANC Study - Pancreatitis: A National Cohort Study
Publicado: (2021)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Biodegradable Polymersomes for the Delivery of Gemcitabine to Panc-1 Cells
por: Sood, Nimil, et al.
Publicado: (2013)

Diagnostic accuracy of contrast-enhanced diffusion-weighted MRI for liver metastases of pancreatic cancer: towards adequate staging and follow-up of pancreatic cancer – DIA-PANC study: study protocol for an international, multicenter, diagnostic trial
por: Litjens, G., et al.
Publicado: (2020)

Effects of disulfiram on apoptosis in PANC-1 human pancreatic cancer cell line
por: Dastjerdi, M. Nikbakht, et al.
Publicado: (2014)

Cytotoxic effect of pyocyanin on human pancreatic cancer cell line (Panc-1)
por: Moayedi, Aylin, et al.
Publicado: (2018)

Metabolic characterization of invaded cells of the pancreatic cancer cell line, PANC‐1
por: Fujita, Mayumi, et al.
Publicado: (2017)

Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma
por: Raghav, Kanwal, et al.
Publicado: (2021)

Emerging Contribution of PancRNAs in Cancer
por: Mercatelli, Neri, et al.
Publicado: (2020)

Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells
por: Hofer, M D, et al.
Publicado: (2004)

(+)-Grandifloracin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death
por: Ueda, Jun-ya, et al.
Publicado: (2013)

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
por: Mohindroo, Chirayu, et al.
Publicado: (2021)

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
por: Katz, Matthew H. G., et al.
Publicado: (2010)

Effect of quercetin on apoptosis of PANC-1 cells
por: Lee, Joo Hyun, et al.
Publicado: (2013)

Isoalantolactone Induces Reactive Oxygen Species Mediated Apoptosis in Pancreatic Carcinoma PANC-1 Cells
por: Khan, Muhammad, et al.
Publicado: (2012)

Ellagic acid inhibits the proliferation of human pancreatic carcinoma PANC-1 cells in vitro and in vivo
por: Cheng, Hao, et al.
Publicado: (2017)

Silencing of Carboxypeptidase E expression inhibits proliferation and invasion of Panc-1 pancreatic cancer cells
por: Lou, Hong, et al.
Publicado: (2022)

Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreatoduodenectomy
por: Liang, Tom Z., et al.
Publicado: (2023)

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience
por: Bagley, Alexander F., et al.
Publicado: (2022)

Selection and Optimization of a Bioink Based on PANC-1- Plasma/Alginate/Methylcellulose for Pancreatic Tumour Modelling
por: Banda Sánchez, Cristina, et al.
Publicado: (2023)

Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC
por: Colbert, Lauren E., et al.
Publicado: (2017)

Investigating pioneer factor activity and its coordination with chromatin remodelers using integrated synthetic oligo assay
por: Chen, Hengye, et al.
Publicado: (2023)

Dynamic changes during the treatment of pancreatic cancer
por: Wolff, Robert A., et al.
Publicado: (2018)

A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer
por: Katz, Matthew, et al.
Publicado: (2015)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
por: Crane, Christopher H., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v7v574g4sc6upgrhc2f5ciraue